Cipla’s US recovery, biosimilar pipeline key to future growth prospects
Cipla's September-quarter earnings suffered due to a high base in its US business. The company reported sequential growth driven by its strong India business and branded prescription therapies. Recent approvals for respiratory products and a growing biosimilar pipeline bolster Cipla's optimism for future growth. Despite declining operating margins, the firm anticipates improvements supported by…
Read original article on Economic Times →Related news
- Werner sees Q4 one-way revenue per total mile up 10% to 13% while cutting 2026 net CapEx to $190M-$205M Business Corporate United States
- Sensata expects Q4 revenue of $942M-$972M and adjusted EPS of $0.95-$0.99 as China auto outlook softens Business Corporate
- Cheesecake Factory forecasts $4.425b revenue for 2027 while planning up to 27 openings Business Corporate
- H2O America narrows 2026 stand-alone adjusted EPS guidance to $3.10-$3.16 while integrating Quadvest Business Corporate
- Beta Bionics expects $124M-$126M 2026 revenue and targets Mint launch in Q1 2027 Business Corporate
- Northeast Bank outlines $1.4B CD rollover with ~50 bps higher costs as it points to $1.58B loan capacity Business Corporate
-
Jio Platforms Listing Today: Rs 30,213 crore IPO eyes strong debut on Dalal Street
Business
Corporate
India
- BAE Systems completes 1st live-fire test of Navy missile launcher War & Defense Weapons & Arms United Kingdom